At the 2026 American Association of Cancer Research (AACR) Annual Meeting, a clear message emerged from National Cancer Institute (NCI) Director Anthony Letai, MD, PhD: cancer research is delivering real progress, but the work is far from over.
According to the 2026 American Cancer Society’s Cancer Statistics report, cancer mortality in the United States (U.S.) has declined by roughly one-third over the past three decades. That progress translates into something deeply meaningful: more time for patients to spend with loved ones, to reach milestones, and to benefit from the next wave of breakthroughs. This has been driven in part by advances in immuno-oncology and immunotherapy, which continue to transform how cancer is treated across an expanding number of diseases.
Yet, significant challenges remain, and new ones continue to emerge. Early-onset cancers are rising at alarming rates — colorectal cancer is now the leading cause of cancer-related death among adults under 50, with incidence climbing by nearly 3% per year in younger age groups.
At the same time, cancer recurrence and treatment resistance remain formidable obstacles, limiting the durability of even the most promising therapies. And for many communities, barriers to prevention, screening, and timely care mean that advances in the lab have yet to translate into equitable outcomes.
A Changing Landscape and Growing Urgency
Cancer is not a single disease with a single solution. It is increasingly understood as complex, evolving, and deeply influenced by each patient’s biology. As a result, the future of cancer care lies in precision medicine — tailoring treatments based on the unique characteristics of a patient’s biology and tumor profile.
Achieving this future requires something critical: data at scale. Today, one of the biggest challenges in advancing immunotherapy is not just generating data, but making it accessible, connecting it, and learning from it in a meaningful way.
Initiatives like the Cancer Research Institute’s (CRI) Discovery Engine are helping to address this gap by generating high-quality genomic, spatial, and cellular data in a standardized, harmonized way — creating a foundational, AI-ready resource that allows researchers to compare results directly across systems. Designed to grow and evolve over time, the Discovery Engine enables researchers to build a deeper, more connected understanding of how and why immunotherapies work, and for whom.
Looking ahead, integrating AI and advanced analytics will be essential to unlocking these biological and clinical insights faster, more efficiently, and more effectively. By creating a resource that can be continuously built upon and shared across the research community, efforts like this have the potential to accelerate discovery, improve precision medicine, and amplify impact over time.
Alongside advances in technology, Dr. Letai emphasized that the cancer research ecosystem itself must evolve: while global biomedical innovation is accelerating, the U.S. must address persistent inefficiencies, particularly in early-phase clinical trials. He pointed directly to the speed at which other countries, including China, are advancing early-stage studies, and emphasized the need for greater coordination across the research ecosystem. Improving trial design, enabling parallel processes, and streamlining regulatory pathways will be essential to ensure that promising ideas move more quickly from the lab to patients.
Investing in the Next Generation of Breakthroughs
One of the most important themes from Dr. Letai’s address was the urgent need to support the researchers who will drive the next generation of discoveries.
Today, many young researchers face significant barriers on the path to establishing their careers, from funding uncertainty to hiring delays. While new funding models aim to support innovative, higher-risk ideas, there is broad recognition that more must be done to sustain and grow this talent pipeline.
Dr. Letai highlighted several NCI initiatives designed to address this directly as part of a broader effort to strengthen training pathways and support innovative research at its earliest stages. His call to action was unambiguous: support and sustain early-stage investigators, because the future of cancer research depends on them.
CRI shares this conviction — and is acting on it. Through the newly launched IGNITE Award, which provides up to five years of catalytic support bridging the postdoctoral and independent faculty stages, and our broader postdoctoral fellowship program, CRI is directly addressing the funding gaps that force too many promising scientists out of the field before their best work can begin. These investments are ultimately about one thing: ensuring that bold, transformative ideas have a real chance to reach patients.
Expanding Access and Reducing Disparities
Another key priority highlighted by Dr. Letai is ensuring that advances in cancer research reach everyone. He pointed to ongoing and future NCI efforts focused on prevention, screening, and access, particularly in underserved and economically marginalized communities where barriers to early detection, diagnosis, and treatment remain significant.
Improving outcomes will require not only scientific innovation, but also stronger connections between researchers, clinicians, and the communities they serve. That includes better communication: helping patients, policymakers, and the general public understand how research translates into new therapies and opportunities for care. Ultimately, progress in cancer research will depend on our ability to reach those who have historically been left behind, working together to ensure that innovation translates into impact for all patients.
Looking Ahead: Precision, Partnership, and Purpose
As Dr. Letai noted — and echoing this year’s AACR Annual Meeting theme — the future of cancer research will be shaped by three guiding principles:
- Precision, through deeper biological understanding and data-driven insights
- Partnership, across researchers, institutions, and patients
- Purpose, in the shared goal of reducing suffering and saving lives
Together, these principles illuminate not only where the field is headed but also the collective responsibility to ensure that scientific progress translates into meaningful impact for patients.
For patients and families, this work represents hope.
For donors and supporters, it represents an opportunity to make a tangible difference.
Because the next breakthrough — and the lives it will change — depends on what we do now.
